Therefore, there seem to be differential roles of NOX1/4 versus NOX2 in modulating lung inflammation in response to ACS, indicating that targeted therapies against NOX1/4 specifically would be more beneficial in treating earlystage COPD. The gene discussed is NOX1; the disease is chronic obstructive pulmonary disease.